EVA制药与杭州市钱塘区签署战略合作协议

Core Insights - EVA Pharma has established a new office in Hangzhou, China, to strengthen its global strategic expansion and commitment to innovation, localization, and global collaboration in the biopharmaceutical ecosystem [1][2] - The new office will focus on research and development of pharmaceutical raw materials, strategic procurement, global supply operations, import and export activities, and future collaborations in finished formulations, vaccines, and bioproducts [1] Company Overview - EVA Pharma is one of the fastest-growing healthcare organizations in the Middle East and Africa, dedicated to improving access to affordable, high-quality medicines with a focus on innovation, development, and sustainable accessibility [2] - The company employs over 5,000 professionals and produces more than one million medical products daily across four internationally recognized innovative manufacturing facilities [2] - EVA Pharma's product portfolio targets twelve therapeutic areas, including anti-infectives, metabolic health, oncology, and pediatrics, to meet local and international demands [2] Industry Context - China's innovation ecosystem, driven by significant national investment, has positioned the country as a global leader in cell and gene therapy (CGT), with Hangzhou at the forefront of this transformation [1] - BioPharma Town in Hangzhou is a core area for the biopharmaceutical industry, attracting innovative companies focused on cutting-edge fields such as mRNA vaccines and CAR-T cell therapy [1]